Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

NCT01316718 is registered in ClinicalTrials.gov with University of Nottingham as lead sponsor.

NCT NCT01316718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01316718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).
Lead sponsor
University of Nottingham
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2011
Completion date
September 30, 2013
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhoea